… In the present study, we aimed to analyse the safety and efficacy of anti-PD-1 … nivolumab
and pembrolizumab,19, 20 our cohort also includes patients with more advanced liver cirrhosis (…

… In this retrospective research, we demonstrate that PD-1-targeted immunotherapy showed
promising efficacy and mild toxicity in a real-world cohort of patients with advanced stage HCC…

… immunotherapy approaches, programmed cell death protein-… Indeed, agents targeting
PD-1/PD-L1 were recently reported … in decompensated chronic advanced liver diseases has also …

… The prognosis for advanced Hepatocellular carcinoma (HCC)is … (PD-1), phase 3 trials failed
to show significant benefit of PD-… In summary, immunotherapy with PD-1 inhibition is feasible …

… This research included 42 ICC patients who received PD-1-targeted immunotherapy …
primary liver cancer. Tumour development and antitumor treatments may affect liver function…

… immunotherapy, and the introduction of immune checkpoint inhibitors has brought fundamental
changes to the treatment of HCC. Programmed cell death protein 1 (PD-1… , we focused on …

… carcinoma (HCC) treated with programmed cell death 1 (PD-1) inhibitors. We aimed to …
this study, 10 (14·49%) patients with advanced HCC treated with anti-PD-1 immunotherapy …

… immune responses via immunotherapies serves as a … HCC is an important target for
immunotherapy as chronic liver … In this study, we focused on a cohort of patients with advanced-…

… -programmed cell death protein-1 immunotherapy has been approved as a new treatment
option for advanced hepatocellular … Furthermore, immunotherapy in combination with targeted …

… respond to anti-PD-1 immunotherapy. Here, we show that … (10) PD-1 expressed on T
cells binds to its ligands PDL1 (B7-… unprecedented response rates in advanced liver cancer.(47) …